Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Banding Together: A Systematic Comparison of The Cancer Genome Atlas and the Mitelman Database.

Denomy C, Germain S, Haave B, Vizeacoumar FS, Freywald A, Weaver BA, Vizeacoumar FJ.

Cancer Res. 2019 Aug 15. pii: canres.0585.2019. doi: 10.1158/0008-5472.CAN-19-0585. [Epub ahead of print]

PMID:
31416843
2.

Humanized yeast genetic interaction mapping predicts synthetic lethal interactions of FBXW7 in breast cancer.

Kirzinger MWB, Vizeacoumar FS, Haave B, Gonzalez-Lopez C, Bonham K, Kusalik A, Vizeacoumar FJ.

BMC Med Genomics. 2019 Jul 27;12(1):112. doi: 10.1186/s12920-019-0554-z.

3.

Targeting the CINful genome: Strategies to overcome tumor heterogeneity.

Cunningham CE, MacAuley MJ, Yadav G, Vizeacoumar FS, Freywald A, Vizeacoumar FJ.

Prog Biophys Mol Biol. 2019 Feb 25. pii: S0079-6107(18)30284-0. doi: 10.1016/j.pbiomolbio.2019.02.006. [Epub ahead of print] Review.

4.

Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells.

Miah S, Bagu E, Goel R, Ogunbolude Y, Dai C, Ward A, Vizeacoumar FS, Davies G, Vizeacoumar FJ, Anderson D, Lukong KE.

BMC Cancer. 2019 Jan 16;19(1):78. doi: 10.1186/s12885-018-5186-8.

5.

A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality.

Parameswaran S, Kundapur D, Vizeacoumar FS, Freywald A, Uppalapati M, Vizeacoumar FJ.

Trends Cancer. 2019 Jan;5(1):11-29. doi: 10.1016/j.trecan.2018.11.001. Epub 2018 Dec 7. Review.

PMID:
30616753
6.

Cell-based high-throughput screen for small molecule inhibitors of Bax translocation.

Hui KK, Dojo Soeandy C, Chang S, Vizeacoumar FS, Sun T, Datti A, Henderson JT.

J Cell Mol Med. 2019 Mar;23(3):1784-1797. doi: 10.1111/jcmm.14076. Epub 2018 Dec 13.

7.

Molecular characterization of an MLL1 fusion and its role in chromosomal instability.

Parameswaran S, Vizeacoumar FS, Kalyanasundaram Bhanumathy K, Qin F, Islam MF, Toosi BM, Cunningham CE, Mousseau DD, Uppalapati MC, Stirling PC, Wu Y, Bonham K, Freywald A, Li H, Vizeacoumar FJ.

Mol Oncol. 2019 Feb;13(2):422-440. doi: 10.1002/1878-0261.12423. Epub 2018 Dec 31.

8.

Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models.

Pinto N, Prokopec SD, Vizeacoumar F, Searle K, Lowerison M, Ruicci KM, Yoo J, Fung K, MacNeil D, Lacefield JC, Leong HS, Mymryk JS, Barrett JW, Datti A, Boutros PC, Nichols AC.

PLoS One. 2018 Nov 12;13(11):e0207152. doi: 10.1371/journal.pone.0207152. eCollection 2018.

9.

Expression-based analyses indicate a central role for hypoxia in driving tumor plasticity through microenvironment remodeling and chromosomal instability.

Jing A, Vizeacoumar FS, Parameswaran S, Haave B, Cunningham CE, Wu Y, Arnold R, Bonham K, Freywald A, Han J, Vizeacoumar FJ.

NPJ Syst Biol Appl. 2018 Oct 24;4:38. doi: 10.1038/s41540-018-0074-z. eCollection 2018.

10.

Discovering Selective Binders for Photoswitchable Proteins Using Phage Display.

Reis JM, Xu X, McDonald S, Woloschuk RM, Jaikaran ASI, Vizeacoumar FS, Woolley GA, Uppalapati M.

ACS Synth Biol. 2018 Oct 19;7(10):2355-2364. doi: 10.1021/acssynbio.8b00123. Epub 2018 Sep 27.

PMID:
30203962
11.

Global phosphoproteomic analysis identifies SRMS-regulated secondary signaling intermediates.

Goel RK, Meyer M, Paczkowska M, Reimand J, Vizeacoumar F, Vizeacoumar F, Lam TT, Lukong KE.

Proteome Sci. 2018 Aug 18;16:16. doi: 10.1186/s12953-018-0143-7. eCollection 2018.

12.

High-throughput testing in head and neck squamous cell carcinoma identifies agents with preferential activity in human papillomavirus-positive or negative cell lines.

Ghasemi F, Black M, Sun RX, Vizeacoumar F, Pinto N, Ruicci KM, Yoo J, Fung K, MacNeil D, Palma DA, Winquist E, Mymryk JS, Ailles LA, Datti A, Barrett JW, Boutros PC, Nichols AC.

Oncotarget. 2018 May 25;9(40):26064-26071. doi: 10.18632/oncotarget.25436. eCollection 2018 May 25.

13.

EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours.

Toosi BM, El Zawily A, Truitt L, Shannon M, Allonby O, Babu M, DeCoteau J, Mousseau D, Ali M, Freywald T, Gall A, Vizeacoumar FS, Kirzinger MW, Geyer CR, Anderson DH, Kim T, Welm AL, Siegel P, Vizeacoumar FJ, Kusalik A, Freywald A.

Oncogene. 2018 Jul;37(30):4073-4093. doi: 10.1038/s41388-018-0228-x. Epub 2018 Apr 27.

14.

FRK inhibits breast cancer cell migration and invasion by suppressing epithelial-mesenchymal transition.

Ogunbolude Y, Dai C, Bagu ET, Goel RK, Miah S, MacAusland-Berg J, Ng CY, Chibbar R, Napper S, Raptis L, Vizeacoumar F, Vizeacoumar F, Bonham K, Lukong KE.

Oncotarget. 2017 Dec 6;8(68):113034-113065. doi: 10.18632/oncotarget.22958. eCollection 2017 Dec 22.

15.

An integrated computational and experimental study uncovers FUT9 as a metabolic driver of colorectal cancer.

Auslander N, Cunningham CE, Toosi BM, McEwen EJ, Yizhak K, Vizeacoumar FS, Parameswaran S, Gonen N, Freywald T, Bhanumathy KK, Freywald A, Vizeacoumar FJ, Ruppin E.

Mol Syst Biol. 2017 Dec 1;13(12):956. doi: 10.15252/msb.20177739.

16.

Biochemical characterization of INTS3 and C9ORF80, two subunits of hNABP1/2 heterotrimeric complex in nucleic acid binding.

Vidhyasagar V, He Y, Guo M, Talwar T, Singh RS, Yadav M, Katselis G, Vizeacoumar FJ, Lukong KE, Wu Y.

Biochem J. 2018 Jan 2;475(1):45-60. doi: 10.1042/BCJ20170351.

17.

The EphB6 receptor is overexpressed in pediatric T cell acute lymphoblastic leukemia and increases its sensitivity to doxorubicin treatment.

El Zawily A, McEwen E, Toosi B, Vizeacoumar FS, Freywald T, Vizeacoumar FJ, Freywald A.

Sci Rep. 2017 Nov 7;7(1):14767. doi: 10.1038/s41598-017-15200-3.

18.

Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer.

Ghasemi F, Black M, Vizeacoumar F, Pinto N, Ruicci KM, Le CCSH, Lowerison MR, Leong HS, Yoo J, Fung K, MacNeil D, Palma DA, Winquist E, Mymryk JS, Boutros PC, Datti A, Barrett JW, Nichols AC.

Oncotarget. 2017 Apr 20;8(42):71512-71519. doi: 10.18632/oncotarget.17292. eCollection 2017 Sep 22.

19.

Molecular characterization of breast cancer cell lines through multiple omic approaches.

Smith SE, Mellor P, Ward AK, Kendall S, McDonald M, Vizeacoumar FS, Vizeacoumar FJ, Napper S, Anderson DH.

Breast Cancer Res. 2017 Jun 5;19(1):65. doi: 10.1186/s13058-017-0855-0.

20.

Enhancing the throughput and multiplexing capabilities of next generation sequencing for efficient implementation of pooled shRNA and CRISPR screens.

Islam MF, Watanabe A, Wong L, Lazarou C, Vizeacoumar FS, Abuhussein O, Hill W, Uppalapati M, Geyer CR, Vizeacoumar FJ.

Sci Rep. 2017 Apr 21;7(1):1040. doi: 10.1038/s41598-017-01170-z.

21.

Multilayered Control of Alternative Splicing Regulatory Networks by Transcription Factors.

Han H, Braunschweig U, Gonatopoulos-Pournatzis T, Weatheritt RJ, Hirsch CL, Ha KCH, Radovani E, Nabeel-Shah S, Sterne-Weiler T, Wang J, O'Hanlon D, Pan Q, Ray D, Zheng H, Vizeacoumar F, Datti A, Magomedova L, Cummins CL, Hughes TR, Greenblatt JF, Wrana JL, Moffat J, Blencowe BJ.

Mol Cell. 2017 Feb 2;65(3):539-553.e7. doi: 10.1016/j.molcel.2017.01.011.

22.

The intrinsically kinase-inactive EPHB6 receptor predisposes cancer cells to DR5-induced apoptosis by promoting mitochondrial fragmentation.

El Zawily AM, Toosi BM, Freywald T, Indukuri VV, Vizeacoumar FJ, Leary SC, Freywald A.

Oncotarget. 2016 Nov 22;7(47):77865-77877. doi: 10.18632/oncotarget.12838.

23.

Therapeutic relevance of the protein phosphatase 2A in cancer.

Cunningham CE, Li S, Vizeacoumar FS, Bhanumathy KK, Lee JS, Parameswaran S, Furber L, Abuhussein O, Paul JM, McDonald M, Templeton SD, Shukla H, El Zawily AM, Boyd F, Alli N, Mousseau DD, Geyer R, Bonham K, Anderson DH, Yan J, Yu-Lee LY, Weaver BA, Uppalapati M, Ruppin E, Sablina A, Freywald A, Vizeacoumar FJ.

Oncotarget. 2016 Sep 20;7(38):61544-61561. doi: 10.18632/oncotarget.11399.

24.

Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment.

Paul JM, Toosi B, Vizeacoumar FS, Bhanumathy KK, Li Y, Gerger C, El Zawily A, Freywald T, Anderson DH, Mousseau D, Kanthan R, Zhang Z, Vizeacoumar FJ, Freywald A.

Oncotarget. 2016 Aug 2;7(31):50027-50042. doi: 10.18632/oncotarget.10569.

25.

Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.

Ward AK, Mellor P, Smith SE, Kendall S, Just NA, Vizeacoumar FS, Sarker S, Phillips Z, Alvi R, Saxena A, Vizeacoumar FJ, Carlsen SA, Anderson DH.

Breast Cancer Res. 2016 Jan 25;18(1):12. doi: 10.1186/s13058-016-0672-x.

26.

A High Through-put Platform for Recombinant Antibodies to Folded Proteins.

Hornsby M, Paduch M, Miersch S, Sääf A, Matsuguchi T, Lee B, Wypisniak K, Doak A, King D, Usatyuk S, Perry K, Lu V, Thomas W, Luke J, Goodman J, Hoey RJ, Lai D, Griffin C, Li Z, Vizeacoumar FJ, Dong D, Campbell E, Anderson S, Zhong N, Gräslund S, Koide S, Moffat J, Sidhu S, Kossiakoff A, Wells J.

Mol Cell Proteomics. 2015 Oct;14(10):2833-47. doi: 10.1074/mcp.O115.052209. Epub 2015 Aug 19.

27.

Corrigendum: Myc and SAGA rewire an alternative splicing network during early somatic cell reprogramming.

Hirsch CL, Akdemir ZC, Wang L, Jayakumaran G, Trcka D, Weiss A, Hernandez JJ, Pan Q, Han H, Xu X, Xia Z, Salinger AP, Wilson M, Vizeacoumar F, Datti A, Li W, Cooney AJ, Barton MC, Blencowe BJ, Wrana JL, Dent SY.

Genes Dev. 2015 Jun 15;29(12):1341. doi: 10.1101/gad.266601.115. No abstract available.

28.

Spindle Checkpoint Factors Bub1 and Bub2 Promote DNA Double-Strand Break Repair by Nonhomologous End Joining.

Jessulat M, Malty RH, Nguyen-Tran DH, Deineko V, Aoki H, Vlasblom J, Omidi K, Jin K, Minic Z, Hooshyar M, Burnside D, Samanfar B, Phanse S, Freywald T, Prasad B, Zhang Z, Vizeacoumar F, Krogan NJ, Freywald A, Golshani A, Babu M.

Mol Cell Biol. 2015 Jul;35(14):2448-63. doi: 10.1128/MCB.00007-15. Epub 2015 May 11.

29.

Myc and SAGA rewire an alternative splicing network during early somatic cell reprogramming.

Hirsch CL, Coban Akdemir Z, Wang L, Jayakumaran G, Trcka D, Weiss A, Hernandez JJ, Pan Q, Han H, Xu X, Xia Z, Salinger AP, Wilson M, Vizeacoumar F, Datti A, Li W, Cooney AJ, Barton MC, Blencowe BJ, Wrana JL, Dent SY.

Genes Dev. 2015 Apr 15;29(8):803-16. doi: 10.1101/gad.255109.114. Epub 2015 Apr 15. Erratum in: Genes Dev. 2015 Jun 15;29(12):1341.

30.

Building high-resolution synthetic lethal networks: a 'Google map' of the cancer cell.

Paul JM, Templeton SD, Baharani A, Freywald A, Vizeacoumar FJ.

Trends Mol Med. 2014 Dec;20(12):704-15. doi: 10.1016/j.molmed.2014.09.009. Epub 2014 Oct 22. Review.

PMID:
25446836
31.

RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs.

Robinson TJ, Liu JC, Vizeacoumar F, Sun T, Maclean N, Egan SE, Schimmer AD, Datti A, Zacksenhaus E.

PLoS One. 2013 Nov 12;8(11):e78641. doi: 10.1371/journal.pone.0078641. eCollection 2013.

32.

A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities.

Vizeacoumar FJ, Arnold R, Vizeacoumar FS, Chandrashekhar M, Buzina A, Young JT, Kwan JH, Sayad A, Mero P, Lawo S, Tanaka H, Brown KR, Baryshnikova A, Mak AB, Fedyshyn Y, Wang Y, Brito GC, Kasimer D, Makhnevych T, Ketela T, Datti A, Babu M, Emili A, Pelletier L, Wrana J, Wainberg Z, Kim PM, Rottapel R, O'Brien CA, Andrews B, Boone C, Moffat J.

Mol Syst Biol. 2013 Oct 8;9:696. doi: 10.1038/msb.2013.54.

33.

High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: interaction with IQ motif-containing factors.

Robinson TJ, Pai M, Liu JC, Vizeacoumar F, Sun T, Egan SE, Datti A, Huang J, Zacksenhaus E.

Cell Cycle. 2013 Sep 15;12(18):3013-24. doi: 10.4161/cc.26063. Epub 2013 Aug 12.

34.

Genome-wide analysis of intracellular pH reveals quantitative control of cell division rate by pH(c) in Saccharomyces cerevisiae.

Orij R, Urbanus ML, Vizeacoumar FJ, Giaever G, Boone C, Nislow C, Brul S, Smits GJ.

Genome Biol. 2012 Sep 10;13(9):R80. doi: 10.1186/gb-2012-13-9-r80.

35.

Global gene deletion analysis exploring yeast filamentous growth.

Ryan O, Shapiro RS, Kurat CF, Mayhew D, Baryshnikova A, Chin B, Lin ZY, Cox MJ, Vizeacoumar F, Cheung D, Bahr S, Tsui K, Tebbji F, Sellam A, Istel F, Schwarzmüller T, Reynolds TB, Kuchler K, Gifford DK, Whiteway M, Giaever G, Nislow C, Costanzo M, Gingras AC, Mitra RD, Andrews B, Fink GR, Cowen LE, Boone C.

Science. 2012 Sep 14;337(6100):1353-6. doi: 10.1126/science.1224339.

36.

Interaction landscape of membrane-protein complexes in Saccharomyces cerevisiae.

Babu M, Vlasblom J, Pu S, Guo X, Graham C, Bean BD, Burston HE, Vizeacoumar FJ, Snider J, Phanse S, Fong V, Tam YY, Davey M, Hnatshak O, Bajaj N, Chandran S, Punna T, Christopolous C, Wong V, Yu A, Zhong G, Li J, Stagljar I, Conibear E, Wodak SJ, Emili A, Greenblatt JF.

Nature. 2012 Sep 27;489(7417):585-9. doi: 10.1038/nature11354. Epub 2012 Sep 2.

PMID:
22940862
37.

Hsp110 is required for spindle length control.

Makhnevych T, Wong P, Pogoutse O, Vizeacoumar FJ, Greenblatt JF, Emili A, Houry WA.

J Cell Biol. 2012 Aug 20;198(4):623-36. doi: 10.1083/jcb.201111105.

38.

Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Marcotte R, Brown KR, Suarez F, Sayad A, Karamboulas K, Krzyzanowski PM, Sircoulomb F, Medrano M, Fedyshyn Y, Koh JLY, van Dyk D, Fedyshyn B, Luhova M, Brito GC, Vizeacoumar FJ, Vizeacoumar FS, Datti A, Kasimer D, Buzina A, Mero P, Misquitta C, Normand J, Haider M, Ketela T, Wrana JL, Rottapel R, Neel BG, Moffat J.

Cancer Discov. 2012 Feb;2(2):172-189. doi: 10.1158/2159-8290.CD-11-0224. Epub 2011 Dec 29.

39.

PhenoM: a database of morphological phenotypes caused by mutation of essential genes in Saccharomyces cerevisiae.

Jin K, Li J, Vizeacoumar FS, Li Z, Min R, Zamparo L, Vizeacoumar FJ, Datti A, Andrews B, Boone C, Zhang Z.

Nucleic Acids Res. 2012 Jan;40(Database issue):D687-94. doi: 10.1093/nar/gkr827. Epub 2011 Oct 18.

40.

Systematic exploration of essential yeast gene function with temperature-sensitive mutants.

Li Z, Vizeacoumar FJ, Bahr S, Li J, Warringer J, Vizeacoumar FS, Min R, Vandersluis B, Bellay J, Devit M, Fleming JA, Stephens A, Haase J, Lin ZY, Baryshnikova A, Lu H, Yan Z, Jin K, Barker S, Datti A, Giaever G, Nislow C, Bulawa C, Myers CL, Costanzo M, Gingras AC, Zhang Z, Blomberg A, Bloom K, Andrews B, Boone C.

Nat Biotechnol. 2011 Apr;29(4):361-7. doi: 10.1038/nbt.1832. Epub 2011 Mar 27.

41.

Genetic interactions reveal the evolutionary trajectories of duplicate genes.

VanderSluis B, Bellay J, Musso G, Costanzo M, Papp B, Vizeacoumar FJ, Baryshnikova A, Andrews B, Boone C, Myers CL.

Mol Syst Biol. 2010 Nov 16;6:429. doi: 10.1038/msb.2010.82.

42.

Synthetic genetic array (SGA) analysis in Saccharomyces cerevisiae and Schizosaccharomyces pombe.

Baryshnikova A, Costanzo M, Dixon S, Vizeacoumar FJ, Myers CL, Andrews B, Boone C.

Methods Enzymol. 2010;470:145-79. doi: 10.1016/S0076-6879(10)70007-0. Epub 2010 Mar 1.

PMID:
20946810
43.

A novel mechanism for SUMO system control: regulated Ulp1 nucleolar sequestration.

Sydorskyy Y, Srikumar T, Jeram SM, Wheaton S, Vizeacoumar FJ, Makhnevych T, Chong YT, Gingras AC, Raught B.

Mol Cell Biol. 2010 Sep;30(18):4452-62. doi: 10.1128/MCB.00335-10. Epub 2010 Jul 20.

44.

Exploiting the determinants of stochastic gene expression in Saccharomyces cerevisiae for genome-wide prediction of expression noise.

Li J, Min R, Vizeacoumar FJ, Jin K, Xin X, Zhang Z.

Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10472-7. doi: 10.1073/pnas.0914302107. Epub 2010 May 20.

45.

The genetic landscape of a cell.

Costanzo M, Baryshnikova A, Bellay J, Kim Y, Spear ED, Sevier CS, Ding H, Koh JL, Toufighi K, Mostafavi S, Prinz J, St Onge RP, VanderSluis B, Makhnevych T, Vizeacoumar FJ, Alizadeh S, Bahr S, Brost RL, Chen Y, Cokol M, Deshpande R, Li Z, Lin ZY, Liang W, Marback M, Paw J, San Luis BJ, Shuteriqi E, Tong AH, van Dyk N, Wallace IM, Whitney JA, Weirauch MT, Zhong G, Zhu H, Houry WA, Brudno M, Ragibizadeh S, Papp B, Pál C, Roth FP, Giaever G, Nislow C, Troyanskaya OG, Bussey H, Bader GD, Gingras AC, Morris QD, Kim PM, Kaiser CA, Myers CL, Andrews BJ, Boone C.

Science. 2010 Jan 22;327(5964):425-31. doi: 10.1126/science.1180823.

46.

Integrating high-throughput genetic interaction mapping and high-content screening to explore yeast spindle morphogenesis.

Vizeacoumar FJ, van Dyk N, S Vizeacoumar F, Cheung V, Li J, Sydorskyy Y, Case N, Li Z, Datti A, Nislow C, Raught B, Zhang Z, Frey B, Bloom K, Boone C, Andrews BJ.

J Cell Biol. 2010 Jan 11;188(1):69-81. doi: 10.1083/jcb.200909013.

47.

A picture is worth a thousand words: genomics to phenomics in the yeast Saccharomyces cerevisiae.

Vizeacoumar FJ, Chong Y, Boone C, Andrews BJ.

FEBS Lett. 2009 Jun 5;583(11):1656-61. doi: 10.1016/j.febslet.2009.03.068. Epub 2009 Apr 5. Review.

48.

Global map of SUMO function revealed by protein-protein interaction and genetic networks.

Makhnevych T, Sydorskyy Y, Xin X, Srikumar T, Vizeacoumar FJ, Jeram SM, Li Z, Bahr S, Andrews BJ, Boone C, Raught B.

Mol Cell. 2009 Jan 16;33(1):124-35. doi: 10.1016/j.molcel.2008.12.025.

49.

Pex19p binds Pex30p and Pex32p at regions required for their peroxisomal localization but separate from their peroxisomal targeting signals.

Vizeacoumar FJ, Vreden WN, Aitchison JD, Rachubinski RA.

J Biol Chem. 2006 May 26;281(21):14805-12. Epub 2006 Mar 21.

50.

The dynamin-like protein Vps1p of the yeast Saccharomyces cerevisiae associates with peroxisomes in a Pex19p-dependent manner.

Vizeacoumar FJ, Vreden WN, Fagarasanu M, Eitzen GA, Aitchison JD, Rachubinski RA.

J Biol Chem. 2006 May 5;281(18):12817-23. Epub 2006 Mar 6.

Supplemental Content

Loading ...
Support Center